280 related articles for article (PubMed ID: 27605067)
1. DNA-based immunotherapy for HPV-associated head and neck cancer.
Aggarwal C
Immunotherapy; 2016 Oct; 8(10):1187-92. PubMed ID: 27605067
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of human papillomavirus type 16 E7-specific T cells against virally infected squamous cell carcinoma of the head and neck.
Albers A; Abe K; Hunt J; Wang J; Lopez-Albaitero A; Schaefer C; Gooding W; Whiteside TL; Ferrone S; DeLeo A; Ferris RL
Cancer Res; 2005 Dec; 65(23):11146-55. PubMed ID: 16322265
[TBL] [Abstract][Full Text] [Related]
3. Induction of MAGE-A3 and HPV-16 immunity by Trojan vaccines in patients with head and neck carcinoma.
Voskens CJ; Sewell D; Hertzano R; DeSanto J; Rollins S; Lee M; Taylor R; Wolf J; Suntharalingam M; Gastman B; Papadimitriou JC; Lu C; Tan M; Morales R; Cullen K; Celis E; Mann D; Strome SE
Head Neck; 2012 Dec; 34(12):1734-46. PubMed ID: 22287423
[TBL] [Abstract][Full Text] [Related]
4. Characterization of the T-Cell Receptor Repertoire and Immune Microenvironment in Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck.
Saloura V; Fatima A; Zewde M; Kiyotani K; Brisson R; Park JH; Ikeda Y; Vougiouklakis T; Bao R; Khattri A; Seiwert T; Cipriani N; Lingen M; Vokes E; Nakamura Y
Clin Cancer Res; 2017 Aug; 23(16):4897-4907. PubMed ID: 28442504
[No Abstract] [Full Text] [Related]
5. Immunotherapy for head and neck cancer patients: shifting the balance.
Turksma AW; Braakhuis BJ; Bloemena E; Meijer CJ; Leemans CR; Hooijberg E
Immunotherapy; 2013 Jan; 5(1):49-61. PubMed ID: 23256798
[TBL] [Abstract][Full Text] [Related]
6. Progress in head and neck cancer immunotherapy: can tolerance and immune suppression be reversed?
Ferris RL
ORL J Otorhinolaryngol Relat Spec; 2004; 66(6):332-40. PubMed ID: 15668533
[TBL] [Abstract][Full Text] [Related]
7. [Immunotherapy: a new alternative treatment for head and neck squamous cell carcinoma].
Bron L; Romero P
Bull Cancer; 2007 Sep; 94(9):793-7. PubMed ID: 17878099
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy for head and neck cancer: latest developments and clinical potential.
Bauml JM; Cohen RB; Aggarwal C
Ther Adv Med Oncol; 2016 May; 8(3):168-75. PubMed ID: 27239235
[TBL] [Abstract][Full Text] [Related]
9. Toxicities of systemic agents in squamous cell carcinoma of the head and neck (SCCHN); A new perspective in the era of immunotherapy.
Saba NF; Mody MD; Tan ES; Gill HS; Rinaldo A; Takes RP; Strojan P; Hartl DM; Vermorken JB; Haigentz M; Ferlito A
Crit Rev Oncol Hematol; 2017 Jul; 115():50-58. PubMed ID: 28602169
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy in head and neck cancer: current practice and future possibilities.
Agada FO; Alhamarneh O; Stafford ND; Greenman J
J Laryngol Otol; 2009 Jan; 123(1):19-28. PubMed ID: 18761763
[TBL] [Abstract][Full Text] [Related]
11. Novel Treatment Options in Head and Neck Cancer.
Schuler PJ; Laban S; Doescher J; Bullinger L; Hoffmann TK
Oncol Res Treat; 2017; 40(6):342-346. PubMed ID: 28521322
[TBL] [Abstract][Full Text] [Related]
12. Tailored immunotherapy for HPV positive head and neck squamous cell cancer.
Gildener-Leapman N; Lee J; Ferris RL
Oral Oncol; 2014 Sep; 50(9):780-4. PubMed ID: 24126224
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy of HPV-associated cancer: DNA/plant-derived vaccines and new orthotopic mouse models.
Venuti A; Curzio G; Mariani L; Paolini F
Cancer Immunol Immunother; 2015 Oct; 64(10):1329-38. PubMed ID: 26138695
[TBL] [Abstract][Full Text] [Related]
14. Immune response during therapy with cisplatin or radiation for human papillomavirus-related head and neck cancer.
Spanos WC; Nowicki P; Lee DW; Hoover A; Hostager B; Gupta A; Anderson ME; Lee JH
Arch Otolaryngol Head Neck Surg; 2009 Nov; 135(11):1137-46. PubMed ID: 19917928
[TBL] [Abstract][Full Text] [Related]
15. Targeting the immune system: novel therapeutic approaches in squamous cell carcinoma of the head and neck.
Hoffmann TK; Bier H; Whiteside TL
Cancer Immunol Immunother; 2004 Dec; 53(12):1055-67. PubMed ID: 15095020
[TBL] [Abstract][Full Text] [Related]
16. The role of HPV status in recurrent/metastatic squamous cell carcinoma of the head and neck.
Misiukiewicz K; Camille N; Gupta V; Bakst R; Teng M; Miles B; Genden E; Sikora A; Posner M
Clin Adv Hematol Oncol; 2014 Dec; 12(12):812-9. PubMed ID: 25674839
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy in head and neck cancer: Harnessing profit on a system disruption.
Rancoule C; Vallard A; Espenel S; Guy JB; Xia Y; El Meddeb Hamrouni A; Rodriguez-Lafrasse C; Chargari C; Deutsch E; Magné N
Oral Oncol; 2016 Nov; 62():153-162. PubMed ID: 27623508
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy for head and neck cancer.
Davidson HC; Leibowitz MS; Lopez-Albaitero A; Ferris RL
Oral Oncol; 2009 Sep; 45(9):747-51. PubMed ID: 19442565
[TBL] [Abstract][Full Text] [Related]
19. Regression of HPV-positive tumors treated with a new Listeria monocytogenes vaccine.
Sewell DA; Douven D; Pan ZK; Rodriguez A; Paterson Y
Arch Otolaryngol Head Neck Surg; 2004 Jan; 130(1):92-7. PubMed ID: 14732776
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy with dendritic cells in an animal model of early pulmonary metastatic squamous cell carcinoma.
Moon JH; Chung MK; Son YI
Laryngoscope; 2012 Nov; 122(11):2442-6. PubMed ID: 22926978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
